Acorda Therapeutics Inc(ACOR) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment of acute migraine. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

Current Price

$4.60

RSI

32.331

Beta:

0.610038

March 16, 2021
243.4M
1.1M

-14.511 %
1.431 %
-232.834 %
86.231 %

$177,693,000
$225,609,000
$449,836,000
$569,376,000
$512,930,000
$492,660,000
-26.966 %
-99.387 %
-26.574 %
11.005 %
4.114 %

$-107,667,000
$-274,248,000
$20,423,000
$-251,885,000
$-41,283,000
$19,369,000
154.719 %
-107.447 %
1333.340 %
-83.610 %
-146.918 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.